Mutations in SIL1 cause Marinesco-Sjögren syndrome, a cerebellar ataxia with cataract and myopathy

Article metrics

Abstract

SIL1 (also called BAP) acts as a nucleotide exchange factor for the Hsp70 chaperone BiP (also called GRP78), which is a key regulator of the main functions of the endoplasmic reticulum. We found nine distinct mutations that would disrupt the SIL1 protein in individuals with Marinesco-Sjögren syndrome, an autosomal recessive cerebellar ataxia complicated by cataracts, developmental delay and myopathy. Identification of SIL1 mutations implicates Marinesco-Sjögren syndrome as a disease of endoplasmic reticulum dysfunction and suggests a role for this organelle in multisystem disorders.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1: Clinical findings, haplotype analysis, map of the MSS region of interest, organization of SIL1 and consequences of in-frame exon deletions.

References

  1. 1

    Marinesco, G., Draganesco, S. & Vasiliu, D. Encephale 26, 97–109 (1931).

  2. 2

    Sewry, C.A., Voit, T. & Dubovitz, V. Ann. Neurol. 24, 576–580 (1988).

  3. 3

    Lagier-Tourenne, C. et al. Eur. J. Hum. Genet. 11, 770–778 (2003).

  4. 4

    Jones, B. et al. Nat. Genet. 34, 29–31 (2003).

  5. 5

    Varon, R. et al. Nat. Genet. 35, 185–189 (2003).

  6. 6

    Chung, K.T., Shen, Y. & Hendershot, L.M. J. Biol. Chem. 277, 47557–47563 (2002).

  7. 7

    Shomura, Y. et al. Mol. Cell 17, 367–379 (2005).

  8. 8

    Schnell, D.J. & Hebert, D.N. Cell 112, 491–505 (2003).

  9. 9

    Alder, N.N., Shen, Y., Brodsky, J.L., Hendershot, L.M. & Johnson, A.E. J. Cell Biol. 168, 389–399 (2005).

  10. 10

    Hendershot, L.M. Mt. Sinai J. Med. 71, 289–297 (2004).

  11. 11

    Boisrame, A., Beckerich, J.M. & Gaillardin, C. J. Biol. Chem. 271, 11668–11675 (1996).

  12. 12

    Rao, R.V., Ellerby, H.M. & Bredesen, D.E. Cell Death Differ. 11, 372–380 (2004).

  13. 13

    Suzuki, Y. et al. Acta Neuropathol. (Berl.) 94, 410–415 (1997).

  14. 14

    Kitao, Y. et al. J. Neurosci. 24, 1486–1496 (2004).

  15. 15

    Tanaka, T. et al. Genes Cells 3, 801–810 (1998).

Download references

Acknowledgements

We thank the members of the families with MSS for their participation in this study; M.C. Walter for clinical work; and N.B. Romero and J.-P. Leroy for immunohistochemical and electron microscopy studies. J.S. was supported by the START program of the medical faculty of Aachen University of Technology and by the Doktor Robert Pfleger-Stiftung. Financial support of the Muscular Dystrophy Campaign to F.M. and M.B. is acknowledged. R.H., H.L., T.V. and J.W. are members of the German network on muscular dystrophies (MD-NET) funded by the German ministry of education and research (BMBF).

Author information

Correspondence to Jan Senderek.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

Supplementary Fig. 1

Expression analysis of the mouse orthologue Bap/Sil1 in tissues targeted by MSS. (PDF 45 kb)

Supplementary Fig. 2

Identification of BAP/SIL1 mutations. (PDF 344 kb)

Supplementary Fig. 3

Characterization of BAP/SIL1 splice site mutations. (PDF 312 kb)

Supplementary Methods (PDF 32 kb)

Rights and permissions

Reprints and Permissions

About this article

Further reading